Hikal Signs Multi-Year Global CDMO Contract with Leading Agrochemical Company
Hikal · Pharmaceuticals & Biotechnology
What the filing says
- Hikal Limited signed a multi-year contract to supply a specialised agrochemical product globally
- Contract follows successful process development and scale-up, with commercial launch expected by end FY 2026–27
- Hikal holds Responsible Care® certification and EcoVadis Gold Medal rating for sustainability performance
Why it's rated notable: The filing reports a signed multi-year CDMO contract but states no contract value, so the level stays at medium.
Original filing
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Electrical Equipment
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Hikal
- Capex / expansionNotableHikal Limited launches new cGMP Panoli facility for Personal Care production
Other order win filings this fortnight
- Sunita Tools Limited receives supply contract for M1 shell forging (6,000 sets)
- Sunita Tools Limited receives OEM qualification and order for forging empty shells
- Garden Reach Shipbuilders & Engineers signs ₹32,000 Crore Indian Navy contract for 5 NGCs
- GRSE signs ₹32,000 crore contract for five Next Generation Corvettes with Indian Navy
- Larsen & Toubro wins significant orders for residential and commercial projects
- Waaree Renewable Technologies signs 5-year O&M contract for 360 MWp solar project
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.